Sixth Element Capital

Sixth Element Capital is a specialist venture capital firm based in the United Kingdom, focused on the oncology sector. The firm manages the CRT Pioneer Fund, a £70 million investment vehicle created in collaboration with Cancer Research UK to accelerate the development of innovative cancer therapies. Sixth Element Capital bridges the "valley of death" by investing in and managing early-stage drug discovery programs, typically advancing them from academic research through to Phase I or II clinical trials. Their business model involves partnering with pharmaceutical companies for late-stage development and commercialization, having successfully licensed multiple programs to global leaders like Merck KGaA. The firm's team brings extensive experience in drug discovery, intellectual property, and corporate finance to maximize the value of oncology assets.